lunes, 17 de diciembre de 2012

POSTMARKETING ADVERSE DRUG EXPERIENCE (PADE)

UCM332013.pdf
Compliance Program: Postmarketing Adverse Drug Experience (PADE) Reporting Inspections

No hay comentarios:

Publicar un comentario